ARECOR PRESENTS POSITIVE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA-RAPID ACTING INSULIN

Link to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®   Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]

ARECOR ANNOUNCES ORAL PRESENTATION OF THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING INSULIN, AT THE AMERICAN DIABETES ASSOCIATION 80TH SCIENTIFIC SESSIONS

Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes […]

ARECOR EXTENDS MULTI-PRODUCT COLLABORATION WITH CLINICAL STAGE BIOTECH

Link to Full Article Arecor innovative product formulations applied to oncology and rare orphan diseases Cambridge, UK, 19 March 2020: Arecor Limited (“Arecor” or “the Company”), the  biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor […]

ARECOR ACHIEVES SECOND LICENSE MILESTONE PAYMENT FROM GLOBAL PHARMACEUTICAL PARTNER

Link to Full Article Arecor formulated biosimilar product progressing through clinical studies Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered […]

ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY

Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]

HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY

Link to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]

ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING FORMULATION OF INSULIN

Link to Full Article Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Cambridge, UK., 5th December 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. […]

ARECOR AND JDRF SIGN A JOINT RESEARCH, DEVELOPMENT AND COMMERCIALISATION AGREEMENT TO DEVELOP A CO-FORMULATION INSULIN FOR THE TREATMENT OF DIABETES

Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]

DOSING COMPLETE IN PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES

Link to Full Article HEADLINE DATA READOUT EXPECTED Q4 2019 Cambridge, UK.,4 October 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 […]

ARECOR SIGNS A NEW FORMULATION EVALUATION AGREEMENT WITH AN EXISTING PARTNER, A MAJOR GLOBAL PHARMACEUTICAL COMPANY

Link to Full Article Cambridge, UK., 9th July 2019: Arecor Ltd (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company. Under this […]